ArticleBMC ophthalmology2018
The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units.
Article in BMC ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Impact of anti-VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta-analysis.Acta ophthalmologica · 2026Pooled it
- The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.Italian journal of pediatrics · 2023Pooled it
- Cost-effectiveness of community-based artificial intelligence screening for retinopathy of prematurity.Journal of global health · 2026Article
- Oxygen therapy-related risk factors for aggressive retinopathy of prematurity in low-risk preterm neonates.Pediatric research · 2026Article
- Comparison of Success Rates Between Laser Photocoagulation and Intravitreal Anti-Vascular Endothelial Growth Factor Injection for the Treatment of Retinopathy of Prematurity in a Tertiary Referral Center: An 11-Year Survey.Journal of clinical practice and research · 2026Article
- AI-guided precision parenteral nutrition for neonatal intensive care units.Nature medicine · 2025Article
- The use of neural networks to determine factors affecting the severity and extent of retinopathy in preterm infants.International journal of retina and vitreous · 2025Article
- Improving ROP management: insights from a comparative analysis of screening and treatment modalities in a tertiary hospital, Pakistan.BMC ophthalmology · 2025Article
- Impacts of sulfate polysaccharide JCS1S2 on retinal neovascularization in oxygen-induced retinopathy rats.Frontiers in pharmacology · 2025Article
- Retinopathy of Prematurity in Eight Portuguese Neonatal Intensive Care Units: Incidence, Risk Factors, and Progression-A Prospective Multicenter Study.Children (Basel, Switzerland) · 2024Article
- Clinical and Demographic Characteristics of Treatment Requiring Retinopathy of Prematurity in Big Premature Infants in Turkiye: Report No. 1 (BIG-ROP Study).Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2024Article
- Influence of Anaemia on Multifactorial Disease Retinopathy of Prematurity: A Prospective Observational Study.Cureus · 2022Article
- Comparison of foveal optical coherence tomography angiography findings between premature children with ROP and non-premature healthy children.Eye (London, England) · 2021Observational
- Mesenchymal stem cell-derived secretomes for therapeutic potential of premature infant diseases.Bioscience reports · 2020Review
- Clinical features and changes of disease spectrum of zone II retinopathy of prematurity: a 10-year review.International journal of ophthalmology · 2020Article
- Speed of Retinal Vascularization in Retinopathy of Prematurity: Risk and Protective Factors.BioMed research international · 2019Article
- Retinal Vascularization Timeline following Intravitreal Bevacizumab Injection in Infants with Retinopathy of Prematurity: A Retrospective Study.Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundRetinopathy of prematurity (ROP) is a vascular proliferative disorder of the developing retina and a significant cause of childhood blindness around the world. The incidence of ROP is affected by many factors, and the incidence rate varies from country to country. The purpose of this study is to report the incidence and risk factors of ROP in neonatal intensive care unit (NICU) of Guangzhou First People's Hospital in China.
methodsA retrospective review was performed on 436 premature infants who were consecutive ROP screened in the NICU of Guangzhou First People's Hospital from March 2013 to October 2017. The single-factor analysis and the logistic multivariate regression analysis were used to detect risk factors of ROP.
resultsTotal 436 premature infants were consecutive ROP screened, 138 (31.65%) were found ROP, and 61(13.99%) were treated. The single-factor analysis revealed that the incidence of ROP was associated with multiple births, gestational age, birth weight, mechanical ventilation, intravascular hemolysis, the number of operations and blood culture results. The logistic multivariate regression analysis revealed that gestational age; birth weight, mechanical ventilation, minimum SaO2 and daily weight gain were independent risk factors for ROP onset. Forty-nine patients underwent retinal laser photocoagulation with recurrence 20 patients. Twelve patients underwent anti-VEGF drug (Ranibizumab) via intraocular injection with 5 patients of recurrence.
conclusionsThe incidence of ROP in NICU of Guangzhou China will match those in middle-income countries, but higher than high-income countries. Anti-VEGF drugs could be preferred as a good treatment method for zone 1 ROP and aggressive posterior ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.